Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects

Tafenoquine is being developed for relapse prevention in Plasmodium vivax malaria. This Phase I, single-blind, randomized, placebo- and active-controlled parallel group study investigated whether tafenoquine at supratherapeutic and therapeutic concentrations prolonged cardiac repolarization in healt...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Pharmacol
Main Authors: Green, Justin A, Patel, Apurva K, Patel, Bela R, Hussaini, Azra, Harrell, Emma J, McDonald, Mirna J, Carter, Nick, Mohamed, Khadeeja, Duparc, Stephan, Miller, Ann K
Formato: Artigo
Idioma:Inglês
Publicado: BlackWell Publishing Ltd 2014
Assuntos:
Drug Safety
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4283056/
https://ncbi.nlm.nih.gov/pubmed/24700490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.302
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares